IntestiCult™ Intestinal Organoid Growth Medium (Human)

IntestiCult™ Organoid Growth Medium (Human)

Cell culture medium for establishment and maintenance of human intestinal organoids

Skip to the beginning of the images gallery

Interested in trying ��ƽ��’s organoid products for your intestinal research? Fill out the form to request information about introductory offers.

IntestiCult™ Organoid Growth Medium (Human)

Cell culture medium for establishment and maintenance of human intestinal organoids

Size

1 Kit Request Pricing

Catalog #

(Select a product)

Cell culture medium for establishment and maintenance of human intestinal organoids

Request Pricing Request Pricing

Product Advantages

Convenient, in vitro system that recapitulates many key characteristics of the adult intestinal epithelium, including intra- and intercellular signaling, self-propagating stem cell niche, and functional transport into and out of the lumen

Complete medium formulation that delivers consistent results

Enables generation of intestinal organoids in one week

Easy-to-use format and optimized protocol

What's Included

IntestiCult™ OGM Human Basal Medium, 50 mL

Organoid Supplement, 50 mL

Request Pricing

Thank you for your interest in this product. Please provide us with your contact information and your local representative will contact you with a customized quote. Where appropriate, they can also assist you with a(n):

Estimated delivery time for your area

Product sample or exclusive offer

In-lab demonstration

By submitting this form, you are providing your consent to ��ƽ�� Technologies Canada Inc. and its subsidiaries and affiliates (“��ƽ��”) to collect and use your information, and send you newsletters and emails in accordance with our privacy policy. Please contact us with any questions that you may have. You can unsubscribe or change your email preferences at any time.

This site is protected by reCAPTCHA and the ��Ի��.

To see all required products for your protocol, please consult the Protocols and Documentation.

Gentle Cell Dissociation Reagent
cGMP, enzyme-free cell dissociation reagent
Organoid Culture Plates
Cell culture plates for easy and reproducible generation of organoids
DMEM/F-12 with 15 mM HEPES
Dulbecco's Modified Eagle's Medium/Nutrient Ham's Mixture F-12 (DMEM/F-12) with 15 mM HEPES buffer
Y-27632 (Dihydrochloride)
RHO/ROCK pathway inhibitor; Inhibits ROCK1 and ROCK2
Labeling Antibodies
Compatible antibodies for purity assessment of isolated cells

What Our Scientist Says

Organoids have truly expanded the limits of what's possible for in vitro studies of the intestinal epithelium. By providing optimized culture media and robust, approachable protocols, we are making these technologies more accessible to researchers.

Ryan ConderAssociate Director, Gastrointestinal Biology

Overview

Model key characteristics of the adult intestinal epithelium using intestinal organoids established and maintained with this complete medium formulation and optimized protocol. Using the easy-to-follow and robust protocol, you can derive organoids from human intestinal crypts in one week; organoid growth across donor samples, including those that are otherwise difficult to grow, is enabled by an enriched stem cell population.

Organoids grown in IntestiCult™ Organoid Growth Medium (Human) incorporate a functional lumen enclosed by a polarized intestinal epithelial cell layer and, for versatile modeling applications, can be further differentiated in 3D or in 2D as submerged monolayers or air-liquid interface (ALI) cultures using IntestiCult™ Organoid Differentiation Medium (Human; Catalog #100-0214).

Applications of intestinal organoid cultures include studying the development and function of intestinal epithelium, modeling intestinal diseases, and screening molecules for both efficacy and toxicity in an intestinal model. Intestinal organoid cultures can also be used for investigation of adult stem cell properties and for regenerative therapy approaches.

Learn how to culture human intestinal organoids in our On-Demand Intestinal Course or browse our Frequently Asked Questions (FAQs) about the organoid workflows using IntestiCult™. Additionally, download our detailed e-book Proven Protocols for Intestinal Organoid Culture: Getting Started with IntestiCult™ for a curated collection of intestinal organoid protocols.

Should you intend to use this product for commercial purposes, please contact HUB Organoids B.V. at for a commercial use license or for clarifications in relation to HUB Organoids B.V. licensing.

Specialized Media

Intestinal Cells

Human

Cell Culture, Differentiation, Expansion, Maintenance, Organoid Culture

IntestiCult

Disease Modeling, Drug Discovery and Toxicity Testing, Epithelial Cell Biology, Stem Cell Biology

More Information

More Information
Safety Statement	CA WARNING: This product can expose you to Progesterone which is known to the State of California to cause cancer. For more information go to

Data Figures

Figure 1. Primary Organoids Grown in IntestiCult™ Organoid Growth Medium (Human) are Fully Mature After 10-14 Days in Culture

Primary organoids were cultured from human colonic biopsy samples and grown in IntestiCult Organoid Growth Medium (Human). Organoids were imaged after (A) two days, (B) six days, (C) eight days and (D) ten days growth.

Figure 2. Organoids Grown in IntestiCult™ Organoid Growth Medium (Human) Display Markers of Human Intestinal Epithelial Cells

Immunofluorescence of organoids grown in IntestiCult™ Organoid Growth Medium (Human) showing colocalization of (A) DAPI, (B) EPCAM and (C) Ki67. (D) A merged image shows the position of actively proliferating (Ki67+) intestinal stem cells within the epithelial layer (EPCAM+).

Figure 3. Forskolin-Induced Swelling of Organoids Grown in IntestiCult™ Organoid Growth Medium (Human)

Organoids were treated with (A) 5 μM Forskolin or (B) DMSO and organoid area was measured at 0 minutes and 120 minutes. (C)Forskolin-treated organoids increased in size 33.5 ± 3.8% compared to 7.5 ± 0.8% for DMSO-treated organoids.

Figure 4. IntestiCult™ Organoid Growth Medium (Human) Supports the Growth of Organoids in Multiple Extracellular Matrices

Intestinal organoid cultures were prepared in IntestiCult™ Organoid Growth Medium (Human) and plated in (A) Matrigel® Growth Factor Reduced Basement Membrane Matrix (Corning® catalog # 356231), (B) Geltrex® LDEV-Free Reduced Growth Factor Basement Membrane Matrix (Gibco™ catalog # A1413202), (C) Cultrex® Reduced Growth Factor Basement Membrane Extract, Type 1 (R&D Systems™ catalog # 3433-005-R1), and (D) Cultrex® Reduced Growth Factor Basement Membrane Extract, Type 2 (R&D Systems™ catalog # 3533-005-02). Organoid cultures are imaged at the end of passage 4. All four extracellular matrices supported robust growth of human intestinal organoids. Scale bars = 250 μm.

Data and images of the MIMETAS OrganoReady Colon Organoid Plate

Figure 5. The MIMETAS OrganoReady® Colon Organoid Platform Uses IntestiCult™ to Create an Advanced Physiologically Relevant Model for Gastrointestinal Toxicity Testing and Barrier Integrity

(A) The OrganoReady® plate highlighting the microfluidic compartments.

(B) Schematic of the OrganoReady® microfluidic compartments where columns 1, 2, and 3 house the medium, a collagen-1 matrix, and the colon organoid tubule, respectively.

(C) Immunofluorescence staining of the colon organoid tubule confirms an adult tissue phenotype with the presence of goblet cells (Muc2), enterocytes (Occludin), and stem cells (Sox9). The 3D-lumenized structure provides apical (Ezrin) and basolateral (Integrin-β4) access to the polarized epithelium. Additionally, the organoid tubules show polarized and modulatable activity of expression of P-glycoprotein (Pgp).

(D) The OrganoReady® Colon Organoid platform supports toxicity testing, as demonstrated by dose-dependent measurements of TEER, LDH, and ATP following exposure to Afatinib (n = 4, N = 2). After 72 hrs of exposure, a dose dependent decrease in TEER, cytotoxicity, and cell viability was observed. For more information, please visit .

Protocols and Documentation

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type

Product Name

Catalog #

Lot #

Language

Document Type

Product Name

Catalog #

06010

Lot #

All

Language

English

Document Type

Product Name

Catalog #

06010

Lot #

All

Language

English

Document Type

Product Name

Catalog #

06010

Lot #

All

Language

English

Document Type

Product Name

Catalog #

06010

Lot #

All

Language

English

Document Type

Product Name

Catalog #

06010

Lot #

All

Language

English

Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Research Area

Workflow Stages

Workflow Stages for Intestinal Epithelial Cell Research

Tissue Dissociation

Cell Culture

Workflow Stages for Organoids

View All

Workflow Stages for Genome Editing

View All

Resources and Publications

Robust and reproducible human intestinal organoid-derived monolayer model for analyzing drug absorption K. Tanaka et al. Scientific Reports 2025 Apr

Abstract

Predicting the absorption of orally administered drugs is crucial to drug development. Current in vitro models lack physiological relevance, robustness, and reproducibility, thus hindering reliable predictions. In this study, we developed a reproducible and robust culture method to generate a human intestinal organoid-derived monolayer model that can be applied to study drug absorption through a step-by-step approach. Our model showed similarity to primary enterocytes in terms of the drug absorption-related gene expression profile, tight barrier function, tolerability toward artificial bile juice, drug transporter and metabolizing enzyme function, and nuclear receptor activity. This method can be applied to organoids derived from multiple donors. The permeability of launched 19 drugs in our model demonstrated a correlation with human Fa values, with an R 2 value of 0.88. Additionally, by combining the modeling and simulation approaches, the estimated FaFg values for seven out of nine drugs, including CYP3A substrates, fell within 1.5 times the range of the human FaFg values. Applying this method to the drug discovery process might bridge the gap between preclinical and clinical research and increase the success rates of drug development.

Differential Cytotoxicity of Surface-Functionalized Silver Nanoparticles in Colorectal Cancer and Ex-Vivo Healthy Colonocyte Models M. Barbalinardo et al. Cancers 2025 Apr

Abstract

This study investigates the use of silver nanoparticles as a potential new treatment for colorectal cancer. Colorectal cancer is one of the most common cancers worldwide, and finding more effective treatments is essential. The researchers tested silver nanoparticles AgNPs with two different surface coatings to see how they affect cancer cells compared to healthy cells. One type of nanoparticles showed significant effects, reducing cancer cell growth and inducing cell death, while the other had minimal impact. These findings suggest that modifying the surface of nanoparticles could help target cancer cells more specifically, leading to treatments that are both more effective and have fewer side effects. This research could pave the way for new therapies for colorectal cancer and other types of cancer, ultimately improving patient outcomes and advancing cancer treatment strategies.

Discovery of Z1362873773: a novel fascin inhibitor from a large chemical library for colorectal cancer A. Rodríguez-Martínez et al. Scientific Reports 2025 Apr

Abstract

Metastasis is one of the leading causes of cancer-related death worldwide. Fascin, a protein that bundles actin filaments to produce protrusions in cancer cells, plays a significant role in the enhancement of cell migration. This protein has been shown that the overexpression of this protein is related to the appearance of different types of cancer, such as colorectal cancer. In this study, we conducted in silico screening of the Enamine library, a compound library with a broad chemical space. Using a ligand-based virtual screening approach based on the pharmacophore model of G2, we identified the predicted inhibitors. First, these compounds were validated by physicochemical analysis. Differential scanning calorimetry (DSF) was used to study the binding between the predicted compounds and fascin protein, followed by an F-actin bundling assay to determine which compounds inhibited the bundling function of fascin. Z1362873773, which exhibited binding to fascin and inhibited F-actin bundling, was further tested in cell cultures to assess its effects on cancer cell viability and migration as well as in organoid models to evaluate potential cytotoxicity. Finally, we established a protocol that can be applied to discover anti-fascin agents from diverse compound libraries. A new molecule has been identified with considerable fascin inhibitory and migration-arresting capacity, which may lead to the development of new therapies to treat cancer. The online version contains supplementary material available at 10.1038/s41598-025-96457-x. Subject terms: Biochemistry, Biophysics, Cancer, Drug discovery, Molecular biology, Virtual drug screening

View All Publications

Related Products

Interested in trying ��ƽ��’s organoid products for your intestinal research? Fill out the form to request information about introductory offers.

Legal Statement:

This product was developed under a license to intellectual property owned by Hubrecht Organoid Technology (HUB). This product is sold for research use only. Purchase of this product does not include the right to use it for drug screening aiming for commercial gain, equipment validation, biobanking, or for other commercial purposes. Purchasers wishing to use the product for purposes other than basic research use should contact HUB at www.huborganoids.nl to obtain a further license. Purchasers may apply for a License from HUB, which will not be unreasonably withheld by HUB.

Quality Statement:

PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT ��ƽ��, REFER TO WWW.��ƽ��.COM/COMPLIANCE.

Safety Statement:

CA WARNING: This product can expose you to Progesterone which is known to the State of California to cause cancer. For more information go to

�����ƽ��

IntestiCult™ Organoid Growth Medium (Human)

Cell culture medium for establishment and maintenance of human intestinal organoids

IntestiCult™ Organoid Growth Medium (Human)

Cell culture medium for establishment and maintenance of human intestinal organoids

Product Advantages

What's Included

Request Pricing

What Our Scientist Says

Overview

More Information

Data Figures

Protocols and Documentation

Applications

Resources and Publications

Educational Materials (62)

Publications (33)

Abstract

Abstract

Abstract

Related Products

Item added to your cart

��ƽ��